Enhanced in vivo bioluminescence imaging using liposomal luciferin delivery system.
To provide a continuous and prolonged delivery of the substrate D-luciferin for bioluminescence imaging in vivo, luciferin was encapsulated into liposomes using either the pH gradient or acetate gradient method. Under optimum loading conditions, 0.17 mg luciferin was loaded per mg of lipid with 90-95% encapsulation efficiency, where active loading was 6 to 18-fold higher than that obtained with passive loading. Liposomal luciferin in a long-circulating formulation had good shelf stability, with 10% release over 3-month storage at 4 degrees C. Pharmacokinetic profiles of free and liposomal luciferin were then evaluated in transgenic mice expressing luciferase. In contrast to rapid in vivo clearance of free luciferin (t(1/2)=3.54 min), luciferin encapsulated into long-circulating liposomes showed a prolonged release over 24h. The first-order release rate constant of luciferin from long-circulating liposomes, as estimated from the best fit of the analytical model to the experimental data, was 0.01 h(-1). Insonation of luciferin-loaded temperature-sensitive liposomes directly injected into one tumor of Met1-luc tumor-bearing mice resulted in immediate emission of light. Systemic injection of luciferin-loaded long-circulating liposomes into Met1-luc tumor-bearing mice, followed by unilateral ultrasound-induced hyperthermia, produced a gradual increase in radiance over time, reaching a peak at 4-7 h post-ultrasound.
Kheirolomoom
Azadeh
A
University of California, Davis, Department of Biomedical Engineering, 451 East Health Sciences Drive, Davis, CA 95616, USA.
Kruse
Dustin E
DE
Qin
Shengping
S
Watson
Katherine E
KE
Lai
Chun-Yen
CY
Young
Lawrence J T
LJ
Cardiff
Robert D
RD
Ferrara
Katherine W
KW
D000818:Animals; D052160:Benzothiazoles / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D045744:Cell Line, Tumor; D002626:Chemistry, Pharmaceutical; D003692:Delayed-Action Preparations; D004339:Drug Compounding; D016503:Drug Delivery Systems; D004355:Drug Stability; D005260:Female; D006863:Hydrogen-Ion Concentration; D006979:Hyperthermia, Induced; D015552:Injections, Intralesional; D007275:Injections, Intravenous; D008081:Liposomes; D008156:Luciferases / Q000235:genetics / Q000378:metabolism; D049449:Luminescence; D049408:Luminescent Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D008325:Mammary Neoplasms, Experimental / Q000201:enzymology / Q000235:genetics / Q000473:pathology*; D051379:Mice; D008822:Mice, Transgenic; D008954:Models, Biological; D010539:Permeability; D012995:Solubility; D013696:Temperature; D014162:Transfection; D014465:Ultrasonics
D052160:Benzothiazoles; C532924:D-luciferin; D003692:Delayed-Action Preparations; D008081:Liposomes; D049408:Luminescent Agents; D008156:Luciferases